On January 24, 2022, BenchSci announced its US$50 million Series C financing round led by funding round led by iNovia Capital and TCV. Bringing their total investment to $123 million, BenchSci will expedite the expansion of its transformative AI-powered software platform that accelerates research in top pharmaceutical companies and over 4,500 leading research centers worldwide.
BenchSci is a global leader in machine learning applications for novel medicine development.
Osler, Hoskin & Harcourt LLP advised BenchSci with a team consisting of Chad Bayne, Justin Dharamdial, Jeremy Lin, Ferial Fekri (Emerging & High Growth Companies) and Christopher Sheridan (Tax).